MISSISSAUGA, ON, April 24 /PRNewswire-FirstCall/ - Vasogen Inc. (NASDAQ: VSGN; TSX:VAS) today announced that Dr. Eldon R. Smith will succeed Terrance H. Gregg as Chairman of its Board of Directors due to the retirement of Mr. Gregg. Mr. Gregg's resignation from Vasogen's Board is due to the requirements of his role as President and CEO of DexCom, Inc.
Dr. Smith, a Vasogen Board member since 1998, is professor emeritus at the University of Calgary, Alberta, where he served as the Dean of the Faculty of Medicine subsequent to being Head of the Department of Medicine and the Division of Cardiology. He is a distinguished clinician and research scientist, who has made major contributions to the Canadian cardiology and medical communities and, in recognition of his outstanding achievements, he was appointed as an Officer of the Order of Canada. In October 2006, Dr. Smith was appointed to chair the steering committee responsible for developing a new Heart Health Strategy to fight heart disease in Canada. Dr. Smith has served as President of the Canadian Cardiovascular Society, Chairman of the Scientific Review Committee of the Heart and Stroke Foundation of Canada, and President of the Association of Canadian Medical Colleges. He is a graduate of Dalhousie University Medical School and completed cardiology and research training at the National Heart Institute, London, U.K., and the National Institutes of Health, Bethesda, Maryland. Dr. Smith also serves on the boards of Canadian Natural Resources Limited and Aston Hill Financial Inc.
Certain statements in this document constitute "forward-looking statements" within the meaning of the United States Private Securities Litigation Reform Act of 1995 and/or "forward-looking information" under the Securities Act (Ontario). These statements may include, without limitation, plans to cPage: 1 2 3 Related biology technology :1
. Vasogen Announces First Quarter 2009 Results2
. Vasogen Announces 2008 Year-End Results3
. Vasogen Announces Sale of Patent Application and Provides Corporate Update4
. Vasogen Complies with NASDAQ Marketplace Rule 4350(c)(1)5
. Vasogen Provides Corporate Update6
. Vasogen Announces Third Quarter 2008 Results7
. Vasogen Announces Second Quarter 2008 Results8
. Vasogen Provides Corporate Update9
. Vasogen to Webcast Presentation at the Rodman & Renshaw 5th Annual Global Healthcare Conference10
. Vasogen Receives NASDAQ Notification Related to Minimum Bid Price11
. Vasogen Announces Implementation of Strategic Restructuring Plan